Performance of self-reported HIV status in determining true HIV status among older adults in rural South Africa: a validation study by Rohr, Julia K. et al.
Performance of self-reported HIV
status in determining true HIV
status among older adults in rural
South Africa: a validation study
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Rohr, J. K., F. Xavier Gómez-Olivé, M. Rosenberg, J. Manne-Goehler,
P. Geldsetzer, R. G. Wagner, B. Houle, et al. 2017. “Performance
of self-reported HIV status in determining true HIV status among
older adults in rural South Africa: a validation study.” Journal of the
International AIDS Society 20 (1): 21691. doi:10.7448/IAS.20.1.21691.
http://dx.doi.org/10.7448/IAS.20.1.21691.
Published Version doi:10.7448/IAS.20.1.21691
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492112
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Research article
Performance of self-reported HIV status in determining
true HIV status among older adults in rural South
Africa: a validation study
Julia K. Rohr1§, F. Xavier Gómez-Olivé1,3, Molly Rosenberg1,4, Jennifer Manne-Goehler5,6, Pascal Geldsetzer5,
Ryan G. Wagner2,9, Brian Houle2,7,8, Joshua A. Salomon5, Kathleen Kahn2,3,9, Stephen Tollman2,3,9,
Lisa Berkman1,10,11 and Till Bärnighausen1,5,12,13
§Corresponding author: Julia Rohr, Center for Population and Development Studies, Harvard University, 9 Bow Street, Cambridge, MA 02138, USA. Tel: (617) 384-7681.
(jkrohr@hsph.harvard.edu)
Abstract
Introduction: In South Africa, older adults make up a growing proportion of people living with HIV. HIV programmes are likely
to reach older South Africans in home-based interventions where testing is not always feasible. We evaluate the accuracy of
self-reported HIV status, which may provide useful information for targeting interventions or offer an alternative to
biomarker testing.
Methods: Data were taken from the Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South
Africa (HAALSI) baseline survey, which was conducted in rural Mpumalanga province, South Africa. A total of 5059
participants aged ≥40 years were interviewed from 2014 to 2015. Self-reported HIV status and dried bloodspots for HIV
biomarker testing were obtained during at-home interviews. We calculated sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) for self-reported status compared to “gold standard” biomarker results. Log-
binomial regression explored associations between demographic characteristics, antiretroviral therapy (ART) status and
sensitivity of self-report.
Results: Most participants (93%) consented to biomarker testing. Of those with biomarker results, 50.9% reported knowing
their HIV status and accurately reported it. PPV of self-report was 94.1% (95% confidence interval (CI): 92.0–96.0), NPV was
87.2% (95% CI: 86.2–88.2), sensitivity was 51.2% (95% CI: 48.2–54.3) and specificity was 99.0% (95% CI: 98.7–99.4).
Participants on ART were more likely to report their HIV-positive status, and participants reporting false-negatives were
more likely to have older HIV tests.
Conclusions: The majority of participants were willing to share their HIV status. False-negative reports were largely explained
by lack of testing, suggesting HIV stigma is retreating in this setting, and that expansion of HIV testing and retesting is still
needed in this population. In HIV interventions where testing is not possible, self-reported status should be considered as a
routine first step to establish HIV status.
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Introduction
The HIV epidemic in South Africa has vastly changed over
the past decade with the expansion of testing, treatment
and prevention programmes, leading to increases in life
expectancy, less HIV transmission and improved economic
productivity [1–6]. Yet, an estimated 24% of HIV-positive
South African adults are undiagnosed [7]. HIV prevention
interventions are often de-coupled from testing, but HIV
status information is important to effectively target inter-
ventions to people who will benefit from them. For exam-
ple, treatment initiation and adherence support, treatment-
as-prevention strategies, medical male circumcision, pre-
exposure prophylaxis and HIV counselling programmes all
benefit from knowing an individual’s HIV status. In popula-
tion-wide initiatives, self-reported status may be a useful
source of information.
Older adults have been neglected in HIV testing initia-
tives, which have traditionally focused on adolescents and
reproductive-age adults <50 years old [2,3,8–10]. Older
adults in sub-Saharan Africa have less knowledge and
awareness of HIV and are less likely to be tested [7,11–
13]. Over 40% of HIV-positive South Africans aged 60 years
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and older do not know their status [7], yet older adults
make up a substantial and growing proportion of people
living with HIV in South Africa [3,14–17]. They are at risk of
HIV acquisition and present unique challenges to HIV care,
such as more rapid disease progression, slower antiretro-
viral therapy (ART) response and complications from cardi-
ometabolic disease co-infections and cognitive decline
[2,8,9,17–35]. More HIV programmes are needed to target
older populations, who are likely to be reached in home-
based interventions where biomarker HIV testing is not
always feasible. Self-reported HIV status may provide useful
information to target interventions or offer an alternative
to biomarker testing [36], though few studies have exam-
ined its validity in sub-Saharan African populations. In
population-based surveys of adults in Kenya (2012 to
2013), Uganda (2011) and Malawi (2010), asking HIV status
was feasible though self-report was somewhat low (26–
47% of the HIV-positive population) partly due to lack of
HIV testing or repeat testing [37,38]. The validity of using
self-reported status as a proxy for biomarker-confirmed
status among older adults in sub-Saharan Africa has not
been examined.
In the ongoing Health and Aging in Africa: A Longitudinal
Study of an INDEPTH Community in South Africa (HAALSI)
study, we have the unique opportunity to investigate the
validity of self-reported HIV status among older adults in
rural South Africa using biomarker HIV status as the “gold
standard”. We establish for the first time the positive pre-
dictive value (PPV) and negative predictive value (NPV),
sensitivity and specificity of HIV status self-report. We
also assess who is most likely to accurately report their
HIV status and what factors influence accurate self-report.
Methods
Study population and data collection
We analysed data from the HAALSI cohort baseline survey,
conducted from November 2014 through November 2015 to
investigate the health and well-being of the older population
in South Africa. Participants were sampled from all individuals
40 years and older and permanently living in the Agincourt
Health and Socio-Demographic Surveillance System
(Agincourt HDSS) site in rural Mpumalanga province [39].
We selected a total of 6281 people, of which 315 were
deceased and 76 had moved out of the study site. Of the
remaining sample, 86% (5059) participated in the survey,
while 7.3% refused, 6.0% were not found and 0.8% were
unable to participate. Future survey rounds are planned to
study changes in health and well-being of cohort members as
they age. Extensive survey and biomarker data were collected
during in-person interviews by trained local fieldworkers, who
used Computer Assisted Personal Interviews to assess physical
and cognitive functioning, cardiometabolic health, economic
well-being and HIV. Ethical approval for HAALSI was obtained
from the University of the Witwatersrand Human Research
Ethics Committee, the Harvard T.H. Chan School of Public
Health Office of Human Research Administration and the
Mpumalanga Provincial Research and Ethics Committee. All
participants provided informed consent prior to being
interviewed.
HIV and ART status were obtained through both self-
report and biomarker testing at time of the interview.
Fieldworkers collected blood via finger prick and prepared
dried bloodspots (DBS). HIV screening and confirmatory
enzyme-linked immunosorbent assays (ELISA) were done
using the Vironostika HIV 1/2 Ag/Ab MicroELISA System
(BioMérieux, Marcy-l’Étoile, France) and the Roche Cobas
E411 Combi Ag, respectively. DBS were also screened for
presence of ART through testing for lamivudine (3TC) and
emtricitabine (FTC), which are the standard second drugs in
both first- and second-line three-drug regimens in South
Africa. Study samples were analysed at the Pharmacokinetic
Laboratory at the University of Cape Town. Presence of
either drug >0.02 µg/mL was considered positive for ART.
HIV testing and status were queried through the follow-
ing questions with no skip pattern: (1) “Have you ever been
tested for HIV?”, (2) “When was the last time you had an
HIV test?”, (3) “Do you know your HIV status?” and (4)
“Have you ever tested positive for HIV?”. We evaluated the
predictive value of question (4). Covariates were similarly
obtained through interview responses and included age,
sex, education, employment, marital status and household
wealth. A wealth index was created based on household
characteristics and ownership of household items, vehicles
and livestock [40].
Analysis
We examined the proportion and characteristics of partici-
pants who consented to DBS biomarker testing compared to
those who did not and used chi-square (Χ2) tests. The analysis
was limited to participants who consented to biomarker test-
ing and had valid test results. Responses to “Have you ever
tested positive for HIV?” were compared to the “gold stan-
dard” biomarker test result. We calculated the question’s PPV
(proportion reporting testing HIV positive who were truly
positive), NPV (proportion reporting not testing HIV positive
who were truly negative), sensitivity (proportion who were
truly HIV positive who reported testing HIV positive) and
specificity (proportion who were truly HIV negative who did
not report testing HIV positive) [41,42]. These parameters
were also calculated among those who reported ever having
an HIV test, among thosewho report knowing their HIV status,
and stratified by age group and sex.
Our secondary analysis examined factors associated with
accurate self-report of HIV-positive status. Demographic
variables and ART status were considered as predictors of
sensitivity of self-report among those who tested HIV posi-
tive, using crude and age- and sex-adjusted log-binomial
regression models [43].
Results
In the HAALSI baseline survey, 4707 (93%) of the 5095
respondents consented to DBS biomarker testing. Valid
results were available for 4560 individuals and were
included in the analytic sample (Figure 1). Of those with
invalid results, 22 had an indeterminate HIV test result, and
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the remainder had either poor quality or not enough spots
collected. The proportions consenting to biomarker testing
were similar among females (93.4%) and males (92.4%) and
were over 90% for all ages. Consent was slightly higher
among those who reported ever having an HIV test
(94.2% vs. 91.1%, Χ2 p < 0.001) and among those who
reported being HIV positive (95.0% vs. 92.8%, Χ2 p = 0.03).
Out of the 4560 individuals with biomarker results,
64.7% reported ever testing for HIV and 58.4% reported
knowing their status (Table 1). All respondents were
asked if they ever tested positive for HIV regardless of
their responses about HIV testing, giving an overall self-
reported HIV prevalence of 12.5%. Measured biomarker
HIV prevalence was 23.0%. Anyone who reported never
having tested positive for HIV, refused or “did not
know” was considered to be self-reported HIV negative
in analysis (Figure 1).
We found that half of those with biomarker results
(50.9%) reported knowing their status and accurately
reported it. Overall, PPV of self-report was 94.1% (95%
confidence interval (CI): 92.0–96.0), NPV was 87.2% (95%
CI: 86.2–88.2), sensitivity was 51.2% (95% CI: 48.2–54.3)
and specificity was 99.0% (95% CI: 98.7–99.4). Restricting
the analysis to those who reported ever testing for HIV or
those who reported knowing their HIV status did not
improve the predictive value, although the sensitivity
increased to 63.2% and 66.2%, respectively (Table 2).
Predictive values were equivalent among males and
females but varied with age (Table 2). PPVs were lower and
NPVswere higher in older age groups, reflecting the lower HIV
prevalence. Sensitivity among 40–49-year-old women was
slightly higher (53.3%; 95% CI: 45.7–60.8) than among men
(45.4%; 95% CI: 37.2–53.6), possibly related to antenatal test-
ing. Yet, the predictive values in the 40–49-year-old age group
HAALSI
baseline
cohort
5059
(85.9%)
Consented to
DBS test
4707 (93.0%)
DBS
biomarker test
results
available
4560 (96.9%)
Yes
571 (12.5%)
True HIV+: 537
(Positive predictive
value = 94.1%)
No
3971 (87.1%)
True HIV-: 3478
(Negative predictive
value = 87.2%)Don’t know
10 (0.2%)
Refused
8 (0.2%)
Self-reported ever
tested positive for
HIV:
Biomarker test result:Sampled6281
Eligible
5890
(93.8%)
Figure 1. HAALSI baseline survey responses to dried bloodspot (DBS) biomarker testing and HIV self-report.
Table 1. Study population characteristics
Population
N (% of
population)
Reported ever had
an HIV test (%)
Reported being
HIV positive (%)
Biomarker tested
HIV positive (%)
Total 4560 64.7 12.5 23.0
Reported ever had an HIV test 2949 (64.7) 100 19.1 28.7
Reported knowing their HIV status 2665 (58.4) 97.9 21.0 30.0
Gender
Males 2097 (46.0) 63.1 12.6 23.0
Females 2463 (54.0) 66.0 12.5 22.9
Age (years)
40–49 814 (17.9) 74.5 19.7 38.1
50–59 1262 (27.7) 73.3 18.3 31.1
60–69 1203 (26.4) 64.7 10.8 20.3
70–79 808 (17.7) 54.0 5.6 11.0
80+ 473 (10.4) 43.1 1.1 2.8
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did not differ substantially by sex (PPV for females was 95.7%
(95% CI: 89.5–98.8) and males was 97.0% (95% CI: 89.5–99.6);
NPV for females was 77.9% (95% CI: 73.6–82.2) andmales was
74.1% (95% CI: 69.1–79.1)).
In the sub-analysis that explored predictors of correct
self-report, regression models showed that there was no
difference in sensitivity between males and females or any
trends by education, employment status or wealth index.
Sensitivity was slightly lower among older age groups
(Supplementary Table 1). Notably, individuals who screened
positive for ART were more likely to report their HIV-posi-
tive status. The age- and sex-adjusted prevalence ratio for
correct self-report for participants on ART vs. not on ART
was 2.66 (95% CI: 2.19–3.23) among individuals reporting
having taken an HIV test. The ART screening results also
show that out of the 48.8% of the HIV-positive population
that does not report their HIV-positive status, 41% are on
ART, providing a minimum estimate for the proportion who
knowingly misreport their status.
Lastly, we considered time since last HIV test as a possi-
ble explanation for why some HIV-positive individuals may
incorrectly report being HIV-negative because respondents
may have acquired HIV during the time since testing. We
found that among all HIV-positive individuals, those who
correctly reported being HIV positive had more recent HIV
tests (56% reported testing in the past year) than those
who incorrectly reported being HIV negative (24% reported
testing in the past year) (Figure 2).
Discussion
In a population-based sample of older adults in rural
South Africa, we found that self-reported HIV status was
highly predictive of biomarker-confirmed HIV status.
This result has important programmatic and policy
implications as HIV testing, prevention and care man-
agement are increasingly needed and targeted towards
older South Africans. Asking HIV status in in-person
interviews was also feasible, and only 8 out of 4560
individuals refused to answer the question about HIV
status.
The high PPV of self-reported HIV status (94.1%) indi-
cates that individuals reporting being HIV positive are
almost certainly HIV positive and should be referred to
counselling for preventing HIV transmission and to deter-
mining ART status for linkage to care. Individuals reporting
being on ART who can demonstrate their ART status may
not need further testing. If an individual reports not being
on ART, they may be linked to post-test counselling while
confirmatory HIV testing is done. HIV care programmes may
save resources by using information from self-reported
status before running unnecessary tests and may cut
down on patient loss to follow-up by not waiting for bio-
marker testing before referring to care.
The NPV of self-reported HIV status is also high at 87.2%,
but there is a >10% chance that an individual who reports
being HIV negative is truly positive. Thus, while individuals
reporting being HIV negative are likely truly negative and
should be referred to counselling for HIV prevention, fol-
low-up HIV testing is still needed for these individuals. HIV
prevention counselling can discuss risk of HIV acquisition
among older adults and promote the importance of testing
or retesting.
Asking additional questions about previous HIV testing
did not improve the predictive value of self-report, as both
PPV and NPV remained essentially the same when limiting
the population to individuals who reported knowing their
status or to those who reported ever having been tested.
Thus, even if an individual reports being HIV negative and
says they know their status or have been tested for HIV
previously, follow-up testing is still needed. We saw differ-
ences in predictive values by age, largely due to the lower
prevalence of HIV among older age groups. Adults
≥80 years old were more likely to correctly report being
HIV negative (NPV: 98%) or incorrectly report being HIV
positive (PPV: 80%), and confirmation of HIV-positive
Table 2. HIV self-report performance criteria
Population PPV (95% CI) (%) NPV (95% CI) (%) Sensitivity (95% CI) (%) Specificity (95% CI) (%)
Total 94.1 (92.0–96.0) 87.2 (86.2–88.2) 51.2 (48.2–54.3) 99.0 (98.7–99.4)
Subgroups
a. Reported ever had an HIV test 94.9 (93.0–96.7) 86.9 (85.6–88.3) 63.2 (59.9–66.4) 98.6 (98.1–99.1)
b. Reported knowing their HIV status 94.6 (92.8–96.4) 87.2 (85.8–88.6) 66.2 (62.9–69.5) 98.4 (97.8–99.0)
c. Gender
Males 94.3 (91.5–97.1) 87.2 (85.7–88.8) 51.6 (47.1–56.0) 99.1 (98.6–99.5)
Females 93.8 (91.1–96.5) 87.2 (85.7–88.6) 51.0 (46.9–55.1) 99.0 (98.6–99.5)
d. Age (years) 40–49 96.3 (93.3–99.2) 76.2 (72.9–79.4) 49.7 (44.1–55.2) 98.8 (97.9–99.8)
50–59 93.5 (90.3–96.7) 82.9 (80.6–85.2) 55.1 (50.2–60.0) 98.3 (97.4–99.1)
60–69 93.9 (89.7–98.0) 88.6 (86.7–90.5) 50.0 (43.7–56.3) 99.2 (98.6–99.7)
70–79 91.1 (78.8–97.5) 93.7 (92.0–95.4) 46.1 (35.7–56.4) 99.4 (98.6–99.9)
80+ 80.0 (28.4–99.5) 98.1 (96.8–99.3) 30.8 (9.1–61.4) 99.8 (98.8–100)
PPV: positive predictive value; NPV: negative predictive value; CI: confidence interval.
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reports may be more important for these individuals. We
found no difference by sex, which was unexpected because
in younger age groups men are typically less likely to test
for HIV and to link to care than women [10,38,44].
While most HIV-positive individuals can be identified
through self-reports, a large proportion of HIV-positive
older adults (51%) remain unidentified through self-
report, and expanding testing to reach older adults is
essential. False-negative reports could be explained by
not having tested for HIV, having an outdated HIV-nega-
tive test result or knowingly misreporting. A sensitivity of
66% among those who report knowing their status is high,
considering the historically high prevalence of HIV-related
discrimination in South Africa, and stigma may decrease
further as testing becomes more commonplace and ART
use expands [45–47]. Being on ART was associated with
higher sensitivity of self-reported HIV status, indicating
that ART use facilitates disclosure and discussion of posi-
tive HIV status..
Our estimate for sensitivity of self-reported HIV status was
higher than studies from earlier years that have evaluated
self-report among sub-Saharan African adults. The Malawi
demographic and health survey from 2010 found 26% sensi-
tivity of self-report for men and 39% for women; the Uganda
AIDS Indicator Survey (AIS) from 2011 found 32% sensitivity
for men and 44% for women; and the Kenya AIS from 2012 to
2013 found 47% sensitivity overall [37,38]. Though these
surveys were conducted among younger adults and in differ-
ent countries, sensitivity may improve with time and more
widespread HIV testing. Testing initiatives, including home-
based and repeat HIV testing, have been increasing in recent
years in South Africa, leading to improved testing coverage
[7,48,49]. Our results indicate that increased testing and
retesting are still needed among older South Africans for
both males and females to improve sensitivity of self-report
and to make progress towards reaching the UNAIDS 90-90-90
targets [50], which are not yet being met in this population
based on self-report of testing and awareness of status.
Our estimates for the predictive value of self-report are
likely representative of the study population. Even though
individuals who were already aware of their HIV status
appeared to be more comfortable consenting to biomarker
testing, the consent rates were high (>90%) among all
segments of the population. Our study was limited by
only evaluating the predictive value of the question “Have
you ever tested positive for HIV?” whereas a question
phrased differently, such as “What is your HIV status?”,
could produce more false-positive reports.
Asking self-reported HIV status was feasible in this
population, and the majority of participants were willing
to disclose their HIV status to local field workers. Our
estimates of sensitivity and specificity can assist research-
ers and policymakers who have self-reported HIV infor-
mation to estimate HIV prevalence. When reaching older
adults in settings where biomarker testing is expensive or
impractical, our estimates for predictive values give
insight into how to best approach HIV interventions.
While testing efforts are still needed, use of self-reported
status should be considered as a low-cost first step to
effectively target HIV programmes and interventions for
older South Africans.
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